Abstract
Inflammatory mechanisms are active in patients with Alzheimer disease. Serum elevations of acute phase proteins such as α1-antichymotrypsin, along with deposition of inflammatory cytokines in the brain, suggest a “cerebral acute phase response” contributing to amyloid deposition and tissue destruction. Activated microglia possessing HLA-DR surface markers accumulate around amyloid plaques. The complement cascade leads to generation of the membrane attack complex, which may directly damage neuronal membranes. This growing body of evidence suggests that empirical trials of anti-inflammatory drugs are now appropriate to test the hypothesis that suppression of these mechanisms will slow the rate of progression of Alzheimer disease. Several drugs useful in the treatment of rheumatic diseases are candidates for study in Alzheimer disease, including glucocorticoids, antimalarial drugs, and colchicine. Pilot studies of the synthetic glucocorticoid prednisone indicate that treatment with a moderate dose is well tolerated in patients with Alzheimer disease, and suppresses serum levels of acute phase proteins. Based on this experience, a multicenter parallel-design placebo-controlled trial has been initiated with the Alzheimer's Disease Cooperative Study to determine whether treatment with prednisone can slow the rate of progression of Alzheimer disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abraham C. R., Selkoe D. J., and Potter H. (1988) Immunohistochemical identification of the serine protease inhibitor alpha-1 antichymotrypsin in the brain amyloid deposits of Alzheimer's disease.Cell 52, 487–501.
Abraham C. R., Shirahama T., and Potter H. (1990) The protease inhibitor α1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein and is localized in specific cells of both normal and diseased brain.Neurobiol. Aging 11, 123–129.
Aisen P. S., Marin D., Altstiel L., Goodwin C., Baruch B., Jacobson R., Ryan T., and Davis K. L. A pilot study of prednisone in Alzheimer's disease.Dementia, in press.
Aisen P. S. and Davis K. L. (1994) Inflammatory mechanisms in Alzheimer's disease: Implications for therapy.Am. J. Psychiatry 151, 1105–1113.
Altstiel L. and Sperber K. (1991) Cytokines in Alzheimer's disease.Prog. Neuro. Psychopharmacol. Biol. Psychiat. 15, 481–495.
Altstiel L. D., Lawlor B., Mohs R., Schmeidler J., Dalton A., Mehta P., and Davis K. (1995) Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients.Dementia 6, 17–20.
Breitner J. C., Gau B. A., Welsh K. A., Plassman B. L., McDonald W. M., Helms M. J., and Anthony J. C. (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.Neurology 44, 227–232.
Brugge K., Katzman R., Hill L. R., Hansen L. A., and Saitoh T. (1992) Serological α1-antichymotrypsin in Down's syndrome and Alzheimer's disease.Ann. Neurol. 32, 193–197.
Campbell I. L., Abraham C. R., Masliah E., Kemper P., Inglis J. D., Oldstone M. B. A., and Mucke L. (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.Proc. Natl. Acad. Sci. USA 90 10,061–10,065.
Chang Y.-H., Silverman S. L., and Paulus H. E. (1987) Colchicine, inDrugs for Rheumatic Disease (Paulus H. E., Furst D. E., and Droomgoole, eds.), pp. 431, Churchhill Livingstone, New York.
DeDuve C., DeBarsy T., Poole B., Trouet A., Tulkens P., and van Hoof F. (1974) Lysosomotropic agents.Biochem. Pharmac. 23, 2495–2531.
Eikelenboom P. and Stam F. C. (1982) Immunoglobulins and complement factors in senile plaques. An immunohistochemical study.Acta Neuropath. (Berl)57, 239–242.
Goldgaber D., Harris H., Hla T., Maciag T., Donnelly R. J., Jacobsen J. S., Vitek M. P., Guiroy D., and Gajdusek D. C. (1989) Interleukin-1 regulates synthesis of amyloid beta protein precursor mRNA in human endothelial cell.Proc. Natl. Acad. Sci. USA 86, 7606–7610.
Griffin W. S., Sheng J. G., Roberts G. W., and Mrak R. E. (1995) Interleukin-1 expression in different plaque types in Alzheimer's diseases: significance in plaque evolution.J. Neuropathol. Exp. Neurol. 54, 276–281.
Grinde B. and Seglen P. O. (1981) Role of microtubuli in lysosomal protein degradation, Hoppe-Seyler's Z.Physiol. Chem. 362, 549–556.
Haga S., Akai K., and Ishii T. (1989) Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody.Acta Neuropathol. 77, 569–575.
HERA Study Group (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA Study.Am. J. Med. 98, 156–168.
Hinds T. R., Kukull W. A., Van Belle G., Schellenberg G. D., Villacres E. C., and Larson E. B. (1994) Relationship between serum α1-antichymotrypsin and Alzheimer's disease.Neurobiol. Aging 15, 21–27.
Kisilevsky R., Boudreau L., and Foster D. (1983) Kinetics of amyloid deposition. II. The effects of dimethylsulfoxide and colchicine therapy.Lab. Invest. 48, 60–67.
Lucca U., Tettamanti M., Forloni G., and Spagnoli A. (1994) Nonsteroidal anti-inflammatory Drug Use in Alzheimer's Disease.Biol. Psychiatry. 36, 854–856.
Matsubara E., Hirai S., Amari H., Shoji M., Yamaguchi H., Okamoto K., Ishiguro K., Harigaya Y., and Wakabayashi W. (1990) Alpha-1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia.Ann. Neurol. 28, 561–567.
McGeer P. L., Itagaki S., Tago H., and McGeer E. G. (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR.Neurosci. Lett. 79, 195–200.
McGeer P. L., Akiyama H., Itagaki S., and McGeer E. G. (1989) Activation of the classical complement pathway in brain tissue of Alzheimer patients.Neurosci. Lett. 107, 341–346.
McGeer P. L. and Rogers J. (1992) Medical hypothesis: antiinflammatory agents as a therapeutic approach to Alzheimer's disease.Neurology 42, 447–449.
Mullins J. F., Watts F. L., and Wilson C. J. (1956) Plaquenil in the treatment of lupus erythematosus.J. Amer. Med. Assoc. 161, 879–888.
Refolo L. M., Sambamurti K., Efthimiopoulos S., Pappolla M. A., and Robakis N. K. (1995) Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs after normal endocytotic internalization.J. Neurosci. Res. 40, 694–706.
Rich J. B., Rasmusson D. X., Folstein M. F., Carson K. A., Kawas C., and Brandt J. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.Neurology 45, 51–55.
Rogers J., Kirby L. C., Hempelman S. R., Berry D. L., McGeer P. L., Kaszniak A. W., Zalinski J., Cofield M., Mansukhani L., Willson P., and Kogan F. (1993) Clinical trial of indomethacin in Alzheimer's disease.Neurology 43, 1609–1611.
Rogers J. (1995) Inflammation as a pathogenic mechanism in Alzheimer's disease.Arzneim-Forsch/Drug Res. 45, 439–442.
Rozemuller J. M., Stam F. C., and Eikelenboom P. (1990) Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease.Neurosci. Lett. 109, 75–78.
Salmeron G. and Lipsky P. E. (1983) Immunosuppressive potential of antimalarials.Am. J. Med. 75(1A), 19–24.
Shirahama T. and Cohen A. S. (1974) Blockage of amyloid induction by colchicine in an animal model.J. Exp. Med. 140, 1102–1107.
Sperber K., Quraishi H., Kalb T. H., Panja A., Stecher V., and Mayer L. (1993) Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of interleukin 1 alpha (IL-1-α) and IL-6 in human monocytes and T cells.J. Rheumatol. 20, 803–808.
Vandenabeele P. and Fiers W. (1991) Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated ‘acute phase response’ in the brain?Immunol. Today 12, 217–219.
Wisniewski H., Wegiel J., Strojny P., Wang K.-C., Kim K.-S., and Burrage T. (1991) Ultrastructural morphology and immunocytochemistry of beta amyloid classical, primitive and diffuse plaques, inFrontiers of Alzheimer Research (Ishii T., ed.), pp. 99–108, Elsevier, Amsterdam.
Zemer D., Pras M., Sohar E., Modon M., Cabili S., and Gafni J. (1986) Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever.N. Engl. J. Med. 314, 1001–1005.
Zemer D., Livneh A., and Langevitz P. (1992) Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever.Ann. Intern. Med. 116, 426.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aisen, P.S. Inflammation and Alzheimer disease. Molecular and Chemical Neuropathology 28, 83–88 (1996). https://doi.org/10.1007/BF02815208
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02815208